Certain Antihypertensives May Slow the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease

Whitney Wharton,Felicia C. Goldstein,Liping Zhao,Kyle Steenland,Allan I. Levey,Ihab Hajjar

DOI: https://doi.org/10.1016/j.jalz.2015.07.394

2015-01-01

Abstract:Antihypertensives that modulate the renin-angiotensin system (RAS) on AD conversion in those with MCI has not been explored. Evidence suggests that blood-brain-barrier (BBB) permeability is necessary for these effects. We assessed the impact of RAS modulation on conversion to AD and cognitive decline in those with MCI, and the impact of BBB permeability and race on these associations. We analyzed data from the National Alzheimer’s Coordinating Center from the NIA-funded Alzheimer’s Disease Centers. We included individuals receiving antihypertensives with MCI at baseline and who had cognitive assessments on at least 2 follow-up visits. Outcomes included conversion to AD and cognitive and functional decline. Of 784 participants (M=75 years, 48% men), 488 were receiving RAS medications. RAS users were less likely to convert to AD (33% vs 40%; p=0.04) and demonstrated slower decline on the Clinical Dementia Rating sum-of-boxes (CDR-SOB, p<0.01) and Digit Span Forward (p=0.02) than non-RAS users. BBB-crossing RAS medications were associated with slower cognitive decline on the CDR-SOB, (p<0.01), the Mini Mental Status Examination, (p<0.01) and the Boston Naming test (p<0.01). RAS medications were somewhat associated with cognitive benefits in African Americans, more so than Caucasians. (MMSE (p=0.05) category fluency (p=0.04) and Digit Span Backwards, p=0.03)). RAS-modulating medications were associated with less conversion to AD. BBB permeability may produce additional cognitive benefit, and African Americans may benefit moreso from RASmodulation than Caucasians. Results highlight the need for trials investigating RAS modulation during prodromal disease stages. Correspondence: Whitney Wharton, Ph.D., Assistant Professor, Emory University School of Medicine, Department of Neurology, WWHC 1841 Clifton Rd., NE, Atlanta, GA 30329, w.wharton@emory.edu, 404.728.6918. Disclosures: Authors have nothing to disclose. HHS Public Access Author manuscript J Am Geriatr Soc. Author manuscript; available in PMC 2016 February 05. Published in final edited form as: J Am Geriatr Soc. 2015 September ; 63(9): 1749–1756. doi:10.1111/jgs.13627. A uhor M anscript